// App-Quantinova.ai

25 : Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.

Researchers

Presenter

  • Hanna Tukachinsky

Principal Investigators

  • Jon Chung

  • Lucas Dennis

  • Bernard Fendler

  • Samantha Morley

  • Lei Zhong

  • Ryon Graf

  • Jeffrey S. Ross

  • Brian M Alexander

  • Wassim Abida

  • Simon Chowdhury

  • Charles J. Ryan

  • Karim Fizazi

  • Anthony A. Golsorkhi

  • Simon Paul Watkins

  • Andrew Simmons

  • Andrea Loehr

  • Jeffrey Venstrom

  • Geoffrey R. Oxnard

Medical Centers

  • Foundation Medicine, Inc, Cambridge, MA

  • Foundation Medicine, Inc, Cambridge, MA

  • Foundation Medicine, Inc, Cambridge, MA

  • Upstate Medical University, Syracuse, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Guys, Kings and St. Thomas Hospitals, and Sarah Cannon Research Institute, London, United Kingdom

  • Vascular Biology Center, Division of Hematology, Oncology & Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Clovis Oncology, Inc., Boulder, CO

  • Clovis Oncology UK, Ltd., Bury St Edmunds, United Kingdom

  • Clovis Onc, San Francisco, CA

  • Clovis Oncology, Inc., Boulder, CO

Locations

  • United States

  • United Kingdom

  • France

Companies

  • Foundation Medicine,

  • Clovis Oncology, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • BRCA mutation

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved